Coelho, Teresa
Ando, Yukio
Benson, Merrill D.
Berk, John L.
Waddington-Cruz, Márcia
Dyck, Peter J.
Gillmore, Julian D.
Khella, Sami L.
Litchy, William J.
Obici, Laura
Monteiro, Cecilia
Tai, Li-Jung
Viney, Nicholas J.
Buchele, Gustavo
Brambatti, Michela
Jung, Shiangtung W.
St. L. O’Dea, Louis
Tsimikas, Sotirios
Schneider, Eugene
Geary, Richard S.
Monia, Brett P.
Gertz, Morie
Clinical trials referenced in this document:
Documents that mention this clinical trial
Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
https://doi.org/10.1007/s40120-021-00235-6
Funding for this research was provided by:
Ionis Pharmaceuticals
Akcea Therapeutics
Article History
Received: 2 December 2020
Accepted: 2 February 2021
First Online: 26 February 2021
Change Date: 15 March 2021
Change Type: Update
Change Details: The article has been revised to include the corresponding author details and to include the affiliation of co-author, S. Tsimikas.